Many parents of children with autism are increasingly turning to a controversial treatment known as leucovorin, a derivative of vitamin B9, following a press conference last year where federal health officials suggested it could benefit many kids with autism. The treatment is being sought even as medical professionals express caution and uncertainty about its efficacy.
Swathi Balantrapu, a mother from Palo Alto, California, has been on a quest to find effective treatments for her 10-year-old son diagnosed with autism. She has explored various options, including applied behavior analysis (ABA) therapy, a traditional approach with evidence backing, and a costly movement program priced at $7,000. Balantrapu also pursued stem cell therapy in Germany, which has cost her family approximately $40,000 over three years.
The recent announcement regarding leucovorin reignited her hope. “I would do anything for my child,” Balantrapu stated. “Maybe there is something to it. It just feels like one last stone unturned.” The federal officials claimed that leucovorin could assist in treating a rare brain condition known as cerebral folate deficiency and that it might benefit “hundreds of thousands” of autistic children.
Interest in leucovorin surged dramatically, leading to the formation of social media groups where parents exchanged information about doctors willing to prescribe the treatment. However, major medical organizations have expressed strong reservations against its routine prescription, creating a rift between parents seeking answers and healthcare providers navigating the complexities of the situation.
Mixed Messages from Health Authorities
Doctors like Dr. Shafali Jeste, a researcher at the University of California, Los Angeles, describe the challenge of addressing the flood of information surrounding leucovorin. “All of a sudden, there’s this onslaught of information being disseminated that we now have to explain, disentangle and interpret,” she remarked. Despite its use in treating cerebral folate deficiency, the drug’s applicability to autism remains contentious.
Just last week, the FDA clarified that its approval for leucovorin was limited to a narrow subset of patients with a specific condition related to cerebral folate transport deficiency, a rare disorder with fewer than 50 known cases globally. “Right now we don’t have sufficient data to say that we could establish efficacy for autism more broadly,” a senior FDA official stated during a briefing.
This retraction did little to quell the enthusiasm among parents, many of whom are still seeking prescriptions. The demand for leucovorin has remained robust, as evidenced by a 71% increase in prescriptions in the last quarter of 2025, according to a recent paper.
Challenges and Concerns in Treatment Options
While some physicians are hesitant to prescribe leucovorin, others have opted to do so selectively. Dr. Frederick Bassal, a child neurologist at the University of California, Davis, noted that many parents left the press conference with the impression that leucovorin was a validated treatment for autism. He emphasized that the claims regarding a significant correlation between autism and cerebral folate deficiency lack sufficient evidence.
Despite these concerns, Balantrapu sought a doctor on social media after her son’s pediatrician refused to prescribe leucovorin. She joined a Facebook group that rapidly amassed around 80,000 members, all sharing their experiences and seeking out prescribers. Groups on WhatsApp and other social media platforms have also emerged, fostering a community that discusses how to administer the drug.
The high demand for leucovorin has created a challenging environment for healthcare providers. Many doctors are grappling with the decision of whether to prescribe a treatment that lacks comprehensive evidence, fearing potential backlash from colleagues. As Dr. Sarah Mohiuddin at Michigan Medicine explained, the situation requires careful risk-benefit analysis, and the usage of leucovorin in children with autism has not been extensively studied.
Concerns about the drug’s safety and efficacy persist, particularly regarding its long-term use. While leucovorin is generally seen as safe, its safety profile in children with autism remains unestablished. Moreover, the dosing protocols have raised eyebrows, as they can be significantly higher than the recommended daily intake of folate.
The implications of increasing demand extend beyond individual patients. Dr. Amer Karam, an oncologist at Stanford Medicine, has raised alarms about potential shortages of leucovorin for cancer patients who rely on the medication. The FDA has already taken steps to address this issue, announcing on January 12, 2026, that it would allow imports of a version sold in Canada due to a domestic shortage.
As the debate continues, there are indications that some physicians are willing to prescribe leucovorin under certain circumstances. Dr. Richard Frye, who operates in private practice, has become a prominent advocate for the drug. He estimates that around 80% of his autism patients receive prescriptions for leucovorin. Frye’s enthusiasm for the treatment stems from his belief in its potential benefits, despite the skepticism from mainstream medicine.
Parents like Balantrapu are faced with the difficult task of navigating the complex landscape of autism treatments. Even when they find a willing prescriber, they often encounter high costs. Balantrapu was quoted an initial visit fee of $1,896 plus a non-refundable $299 deposit at Frye’s clinic, with follow-up visits priced at $948. Many parents are prepared to invest considerable resources to improve their children’s lives, yet the uncertainties surrounding leucovorin’s efficacy leave them with tough choices.
In conclusion, the growing interest in leucovorin reflects a broader struggle faced by parents of children with autism. As they seek out new treatments, the divide between families and healthcare providers continues to widen. The challenge lies in balancing the desperate hopes of parents with the principles of evidence-based medicine, a balance that is increasingly difficult to maintain.
